Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer

NCT03455556 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03455556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Terminated
Start date
August 10, 2018
Completion date
January 7, 2020
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

mesothelin positive, stage iii non-small cell lung cancer ajcc v7, stage iiia non-small cell lung cancer ajcc v7, stage iiib non-small cell lung cancer ajcc v7, stage iv non-small cell lung cancer ajcc v7